Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23362601 | 0.84 | ADRA2A (0.33) | MAP3K14ADRA2AF2F9F10 | |
| SCHEMBL9787028 | 0.84 | MAP3K14 (0.31) | MAP3K14ADRA2AF2F9F10 | |
| SCHEMBL27859985 | 0.78 | MAP3K14 (0.51) | MAP3K14ADRA2A | |
| SCHEMBL21436437 | 0.78 | MAP3K14 (0.51) | MAP3K14ADRA2A | |
| SCHEMBL1265783 | 0.78 | MAP3K14 (0.51) | MAP3K14ADRA2A | |
| SCHEMBL28703563 | 0.77 | MAP3K14 (0.32) | MAP3K14ADRA2A | |
| Hydrochloric Acid SCHEMBL1066097 | 0.77 | MAP3K14 (0.50) | MAP3K14ADRA2A | |
| Hydrochloric Acid SCHEMBL30563619 | 0.77 | MAP3K14 (0.50) | MAP3K14ADRA2A | |
| Hydrochloric Acid SCHEMBL1066095 | 0.77 | MAP3K14 (0.50) | MAP3K14ADRA2A | |
| Hydrochloric Acid SCHEMBL26962503 | 0.77 | MAP3K14 (0.50) | MAP3K14ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| CN-103183660-A | Chromane derivative used as TRPV3 (transient receptor potential vanilloid 3) conditioning agent | GLENMARK PHARMACEUTICALS SA | 2013-07-03 | — | — | CN | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2254879-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009084034-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | MAP3K14 882/4885ADRA2A 207/4885F2 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.